Suppr超能文献

带有删失数据的交叉试验的分层秩检验。

A hierarchical rank test for crossover trials with censored data.

机构信息

Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.

出版信息

Stat Med. 2011 Dec 30;30(30):3507-19. doi: 10.1002/sim.4398. Epub 2011 Dec 5.

Abstract

We propose an approach to analyze survival time in a crossover clinical trial by performing a primary ranking on whether events occur and a secondary ranking on event times. This hierarchical ranking method is meant to reflect the idea that the goal of therapy is to prevent a clinical event and, failing that, to delay the occurrence of the event, hopefully for a substantial amount of time. We compare our approach with other methods including one method proposed by Feingold and Gillespie, a recommended procedure. The power is similar in many settings, but the hierarchical ranking can have substantially greater power under certain censoring patterns and also under a cure model, or models where treatment induces a substantial delay in some fraction of patients. We additionally feel that the hierarchical ranking method should be more clinically relevant in many settings. The method can also be applied to continuous outcomes censored by a limit of detection, such as HIV viremia.

摘要

我们提出了一种在交叉临床试验中分析生存时间的方法,方法是对是否发生事件进行主要排序,并对事件时间进行次要排序。这种层次排序方法旨在反映这样一种理念,即治疗的目标是预防临床事件,而如果未能做到这一点,则希望延迟事件的发生,最好是在相当长的一段时间内。我们将我们的方法与其他方法进行了比较,包括 Feingold 和 Gillespie 提出的一种方法,这是一种推荐的方法。在许多情况下,功效相似,但在某些删失模式下,以及在治愈模型下,或者在治疗导致某些患者出现实质性延迟的情况下,层次排序方法的功效可以大大提高。我们还认为,在许多情况下,层次排序方法在临床方面应该更具相关性。该方法还可以应用于通过检测极限进行连续结果删失的情况,例如 HIV 病毒载量。

相似文献

1
A hierarchical rank test for crossover trials with censored data.
Stat Med. 2011 Dec 30;30(30):3507-19. doi: 10.1002/sim.4398. Epub 2011 Dec 5.
2
Incorporating baseline measurements into the analysis of crossover trials with time-to-event endpoints.
Stat Med. 2018 Oct 15;37(23):3280-3292. doi: 10.1002/sim.7834. Epub 2018 Jun 11.
3
Assessing temporal agreement between central and local progression-free survival times.
Stat Med. 2015 Feb 28;34(5):844-58. doi: 10.1002/sim.6371. Epub 2014 Nov 13.
4
6
A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.
Biostatistics. 2013 Jul;14(3):409-21. doi: 10.1093/biostatistics/kxs057. Epub 2013 Jan 10.
7
Weighted win loss approach for analyzing prioritized outcomes.
Stat Med. 2017 Jul 10;36(15):2452-2465. doi: 10.1002/sim.7284. Epub 2017 Mar 26.
8
RMST for Interval-Censored Data in Oncology Clinical Trials.
Stat Med. 2025 Feb 28;44(5):e70012. doi: 10.1002/sim.70012.
9
Testing for qualitative heterogeneity: An application to composite endpoints in survival analysis.
Stat Methods Med Res. 2019 Jan;28(1):151-169. doi: 10.1177/0962280217717761. Epub 2017 Jul 3.
10
Sample size calculation for mixture cure model with restricted mean survival time as a primary endpoint.
Stat Methods Med Res. 2024 Sep;33(9):1546-1558. doi: 10.1177/09622802241265501. Epub 2024 Aug 6.

引用本文的文献

1
A New Method for Imputing Censored Values in Crossover Designs with Time-to-Event Outcomes Using Median Residual Life.
Biomed Res Int. 2020 Dec 10;2020:8475154. doi: 10.1155/2020/8475154. eCollection 2020.

本文引用的文献

1
Cross-over trials in Statistics in Medicine: the first '25' years.
Stat Med. 2006 Oct 30;25(20):3430-42. doi: 10.1002/sim.2706.
2
Regression analysis based on pairwise ordering of patients' clinical histories.
Stat Med. 2002 Nov 30;21(22):3353-67. doi: 10.1002/sim.1272.
3
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.
N Engl J Med. 2000 Mar 30;342(13):921-9. doi: 10.1056/NEJM200003303421303.
4
Rule-based ranking schemes for antiretroviral trials.
Stat Med. 1997 May 30;16(10):1175-91. doi: 10.1002/(sici)1097-0258(19970530)16:10<1175::aid-sim522>3.0.co;2-g.
5
Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP).
Stat Med. 1997 Mar 30;16(6):681-93. doi: 10.1002/(sici)1097-0258(19970330)16:6<681::aid-sim487>3.0.co;2-h.
6
Cross-over trials with censored data.
Stat Med. 1996 May 30;15(10):953-67. doi: 10.1002/(SICI)1097-0258(19960530)15:10<953::AID-SIM213>3.0.CO;2-M.
10
The analysis of failure time data in crossover studies.
Stat Med. 1991 Jul;10(7):1099-113. doi: 10.1002/sim.4780100710.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验